Compounded Semaglutide: What It Is, How It Works, and What to Know Before You Start

What Compounded Semaglutide Actually Is

Compounded semaglutide is semaglutide base or a semaglutide salt (most commonly semaglutide sodium or acetate) prepared by a licensed compounding pharmacy rather than by Novo Nordisk's manufacturing process. It is not a generic drug. No FDA-approved generic semaglutide exists as of early 2025, because semaglutide is a biologic peptide and the abbreviated new drug application (ANDA) pathway does not apply. Instead, these products are made under Section 503A (patient-specific, traditional compounding pharmacies) or Section 503B (outsourcing facilities that can produce larger batches without patient-specific prescriptions) of the Federal Food, Drug, and Cosmetic Act.

The FDA permits compounding of a drug that is on its drug shortage list. Semaglutide injections appeared on that list beginning in 2022, which opened the door for widespread compounded dispensing. The agency removed finished semaglutide drug products from the shortage list in late 2024, triggering a wind-down period for 503A pharmacies (generally several months) and a separate, longer transition for 503B outsourcing facilities. Patients and prescribers should confirm current shortage status directly at FDA Drug Shortages before initiating or continuing compounded therapy.

The branded reference products, Wegovy (semaglutide 2.4 mg weekly injection, approved for chronic weight management) and Ozempic (semaglutide 0.5 to 2 mg weekly injection, approved for type 2 diabetes), have published prescribing labels with full pharmacokinetic data, excipient profiles, and post-marketing safety surveillance Wegovy FDA label. Compounded versions have not undergone that same pre-market review.

How Semaglutide Works in the Body

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to food. It binds receptors in the pancreas to increase glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce caloric intake. Semaglutide's half-life of approximately 165 to 184 hours makes once-weekly dosing viable, whereas native GLP-1 has a half-life under two minutes.

The molecule works regardless of whether it was manufactured by Novo Nordisk or prepared at a compounding pharmacy, provided the amino-acid sequence and structural integrity are preserved. That conditional is the source of regulatory and clinical concern. Peptide stability depends on pH, temperature, and excipient choice. Compounding pharmacies that substitute the base form or add novel excipients (for example, vitamin B12 or cyanocobalamin, which some have marketed as "enhanced" formulations) create a product that has not been evaluated for bioequivalence. The FDA issued a safety communication in October 2024 specifically warning that compounded semaglutide products with added ingredients are not FDA-approved and carry unknown risk profiles.

The Clinical Evidence Behind Branded Semaglutide

The STEP trial program is the primary evidence base. STEP-1 (N=1,961 to 68 weeks) randomized adults with BMI ≥30, or BMI ≥27 with at least one comorbidity and no type 2 diabetes, to semaglutide 2.4 mg subcutaneous weekly versus placebo plus lifestyle intervention. Participants on semaglutide lost a mean 14.9% of body weight compared with 2.4% on placebo (P<0.001). Roughly 86% of semaglutide-treated patients lost at least 5% of body weight. [1]

STEP-3 (N=611 to 68 weeks) tested semaglutide 2.4 mg alongside intensive behavioral therapy. Mean weight loss reached 16.0% with semaglutide vs. 5.7% with placebo, demonstrating that the drug effect is additive to, not a replacement for, lifestyle modification. [3]

STEP-5 extended observation to 104 weeks (N=304) and found sustained mean weight loss of 15.2% with continued semaglutide, while the placebo group regained most lost weight after week 60. [4] Drug discontinuation, not duration, determines regain risk.

For cardiovascular outcomes, the SELECT trial (N=17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes) found semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE: cardiovascular death, nonfatal MI, nonfatal stroke) by 20% versus placebo over a mean follow-up of 33.4 months (HR 0.80 to 95% CI 0.72, 0.90, P<0.001). [5] This was the first dedicated cardiovascular outcomes trial for a weight-management GLP-1, and the result influenced updated prescribing discussions in cardiology and obesity medicine.

In type 2 diabetes, STEP-2 (N=1,210 to 68 weeks) showed semaglutide 2.4 mg produced 9.6% weight loss versus 3.4% with placebo, with meaningful HbA1c reductions alongside weight benefit. [2]

Compounded vs. Branded Semaglutide: What Is and Is Not the Same

The active molecule is the same, assuming the compounding pharmacy uses pharmaceutical-grade semaglutide API with verified purity. The differences lie elsewhere.

Manufacturing oversight. Novo Nordisk's Wegovy and Ozempic are produced under FDA Current Good Manufacturing Practice (cGMP) standards, with validated sterility testing, endotoxin limits, and device testing for the auto-injector pen. Compounding pharmacies operate under cGMP-equivalent standards for 503B facilities, but 503A pharmacies face less intensive FDA inspection cycles. The FDA issued warning letters to multiple 503B outsourcing facilities in 2023 and 2024 for sterility deficiencies in injectable peptide production.

Excipients and added substances. Branded Wegovy contains semaglutide, disodium phosphate dihydrate, propylene glycol, phenol, and water for injection. Some compounded products have added cyanocobalamin (vitamin B12), L-carnitine, or other compounds marketed as metabolic co-factors. None of these combinations has been studied in a randomized trial. The FDA's October 2024 communication specifically named these formulations as a safety concern.

Dose accuracy. Injectable peptides at microgram concentrations require precise fill-finish processes. An independent 2023 analysis by the Alliance for Pharmacy Compounding found concentration variability of up to 15% across sampled compounded semaglutide vials, compared with plus or minus 3% for commercial Wegovy pens.

Cost. Branded Wegovy lists at approximately $1,349 per month (Novo Nordisk 2024 WAC). Compounded semaglutide through telehealth platforms typically runs $199 to $399 per month depending on dose and provider. Insurance coverage for Wegovy remains inconsistent; most commercial plans cover Ozempic for type 2 diabetes but exclude Wegovy for weight loss, and Medicare Part D excludes anti-obesity medications by statute.

The HealthRX clinical team uses a four-factor decision framework when evaluating compounded vs. branded semaglutide for a patient: (1) confirmed pharmacy 503B status and current FDA inspection history, (2) certificate of analysis from the active pharmaceutical ingredient supplier showing purity ≥98%, (3) absence of unapproved added substances, and (4) verification that the semaglutide shortage declaration is still active for the patient's dispensing date. Any compounded product that fails criteria 1 through 4 should prompt a transition plan to branded product or an alternative.

Semaglutide vs. Tirzepatide (Mounjaro and Zepbound): How Do They Compare?

Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for obesity) acts on two incretin receptors simultaneously: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). The dual mechanism appears to produce greater weight loss in head-to-head trial designs than semaglutide alone, though no direct randomized comparison of semaglutide 2.4 mg versus tirzepatide exists in a single registered trial as of early 2025.

SURMOUNT-1 (N=2,539 to 72 weeks) tested tirzepatide 5 mg, 10 mg, and 15 mg versus placebo in adults with obesity or overweight with comorbidities. Mean body-weight reduction at the 15 mg dose was 22.5% versus 2.4% with placebo (P<0.001). At 10 mg, the reduction was 21.4%. [6] Comparing these figures with STEP-1's 14.9% suggests a meaningful clinical gap, though cross-trial comparisons carry confounding risk (different populations, titration schedules, and co-interventions).

SURMOUNT-4 (N=670 to 88 weeks) examined what happens when tirzepatide is withdrawn after 36 weeks of therapy. Patients who continued tirzepatide lost an additional 5.5% body weight through week 88, while those switched to placebo regained a mean 14% of body weight. [8] This reinforces a pattern consistent with STEP-5: weight is regained after stopping any GLP-1 or dual GIP/GLP-1 agonist.

In type 2 diabetes, SURMOUNT-2 (N=938 to 72 weeks) showed tirzepatide 15 mg produced 15.7% weight loss versus 3.3% with placebo in patients with T2D and obesity. [7]

For patients who have not responded adequately to semaglutide 2.4 mg after 16 weeks of maintenance dosing, transitioning to tirzepatide is a reasonable next step per the American Association of Clinical Endocrinology (AACE) 2016 obesity guidelines framework, which recommends reassessing pharmacotherapy response at defined intervals. [9] The Zepbound FDA label specifies the approved titration schedule for tirzepatide in the obesity indication.

Compounded tirzepatide exists under similar shortage-based rules as compounded semaglutide. The FDA placed tirzepatide injections on the shortage list in 2022 and removed them in mid-2024, with analogous wind-down timelines. Patients considering compounded tirzepatide face the same manufacturing-quality considerations described above for compounded semaglutide.

Dosing and Titration for Compounded Semaglutide

Compounded semaglutide prescriptions typically mirror the Wegovy titration schedule because prescribers use the branded label as a clinical reference. The standard titration runs as follows:

• Weeks 1 through 4: 0.25 mg subcutaneous weekly
• Weeks 5 through 8: 0.5 mg subcutaneous weekly
• Weeks 9 through 12: 1.0 mg subcutaneous weekly
• Weeks 13 through 16: 1.7 mg subcutaneous weekly
• Week 17 onward (maintenance): 2.4 mg subcutaneous weekly

Slower titration is appropriate for patients with significant nausea or gastrointestinal side effects. The most common adverse events across STEP trials were nausea (44% semaglutide vs. 16% placebo in STEP-1), diarrhea (30% vs. 16%), vomiting (24% vs. 6%), and constipation (24% vs. 11%). [1] Most GI symptoms were mild-to-moderate and transient, peaking during dose escalation.

Contraindications from the Wegovy label include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), and known hypersensitivity to semaglutide. Pancreatitis has been reported; clinicians should assess amylase and lipase if patients develop persistent severe abdominal pain. The same contraindications apply when prescribing compounded semaglutide, because the active molecule is the same.

The FDA Regulatory Picture in 2025

The FDA's position on compounded semaglutide shifted materially in late 2024. After confirming that commercial supply of Wegovy and Ozempic had recovered sufficiently, the agency removed finished semaglutide injection from the shortage list. This triggers a grace period for pharmacies.

503A pharmacies (traditional compounders filling patient-specific prescriptions) must stop producing compounded semaglutide once the shortage is no longer declared, with limited exceptions for patients with documented allergy to a branded excipient or another clinically justified reason. 503B outsourcing facilities received a longer transition window, with the FDA stating it would exercise enforcement discretion through a stated deadline to allow patients to transition to commercial products.

The FDA has been explicit that compounding semaglutide with added substances such as cyanocobalamin or other non-semaglutide active ingredients is not a valid exception to the shortage-based compounding authorization, even during the shortage period. Telehealth platforms and pharmacies marketing "enhanced semaglutide" with add-on compounds should be approached with significant caution.

Patients currently receiving compounded semaglutide should ask their prescriber: Is this pharmacy 503A or 503B? Has the shortage declaration expired for my dispensing state? Does the product contain any active substance beyond semaglutide base? These three questions determine whether the current supply is on solid regulatory ground.

Who Is an Appropriate Candidate?

The Wegovy label defines the approved population as adults with a BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. The same clinical criteria are reasonable for prescribing compounded semaglutide, because the prescriber is using the branded molecule's evidence base to justify the prescription.

The AACE/ACE 2016 obesity clinical practice guidelines state: "The decision to use pharmacotherapy for weight management should be based on the patient's risk-benefit profile, including the degree of obesity, comorbidities, previous weight loss attempts, and patient preference." [9] That standard applies whether the dispensed product is branded or compounded.

Patients with type 2 diabetes whose primary goal is glycemic control, not weight, are candidates for Ozempic (approved for T2D at 0.5 to 2 mg weekly) rather than the weight-management label. Compounded semaglutide at doses targeting 2.4 mg is most relevant to the weight-management indication.

STEP-8 (N=338 to 68 weeks) compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily in patients with overweight or obesity. Semaglutide produced 15.8% mean weight loss versus 6.4% with liraglutide (P<0.001), providing head-to-head evidence that once-weekly semaglutide outperforms once-daily liraglutide for weight reduction. [10] This comparison matters for patients asking whether older GLP-1 options like Saxenda (liraglutide 3.0 mg) represent a reasonable compounded alternative.

Monitoring and Long-Term Considerations

Patients on any semaglutide formulation should have baseline and periodic monitoring of: body weight and BMI every 4 weeks during titration, HbA1c and fasting glucose (especially in pre-diabetes), heart rate (semaglutide produces a mean resting heart rate increase of approximately 2 to 3 beats per minute), and symptoms of pancreatitis or gallbladder disease (cholelithiasis risk is elevated; 1.6% semaglutide vs. 0.7% placebo in STEP-1). [1]

STEP-5's 104-week data confirm that semaglutide's weight-loss benefit is sustained with continuous therapy: the 15.2% mean loss at 104 weeks is comparable to the 68-week result, indicating no meaningful tachyphylaxis over two years. [4] That duration of evidence matters when counseling patients about long-term treatment expectations.

Muscle mass preservation is a growing concern with all GLP-1 and dual agonist therapies. A 2023 analysis published in the journal Obesity found that approximately 25 to 40% of weight lost on semaglutide may be lean mass, not fat mass alone. Resistance training and adequate dietary protein (at least 1.2 g per kg of body weight per day) may mitigate lean-mass loss, though no large randomized trial has specifically tested that intervention alongside semaglutide 2.4 mg.

For patients who achieve target weight or plateau on semaglutide 2.4 mg, escalation to tirzepatide 15 mg is the most evidence-supported next step given SURMOUNT-1's 22.5% weight-loss result at the highest dose. [6] A prescriber should document the clinical rationale for switching, especially if transitioning from a compounded to a branded product or vice versa.

Compounded Semaglutide Cost and Access

The price differential between compounded and branded semaglutide is the primary driver of patient interest. At Novo Nordisk's 2024 wholesale acquisition cost, Wegovy runs approximately $1,349 per month and Ozempic approximately $968 per month without insurance. Most telehealth platforms offering compounded semaglutide price the full titration starting kit at $199 to $299 for the first month, with maintenance-dose pricing of $299 to $399 per month.

Insurance coverage gaps explain much of the demand. Medicare Part D is statutorily prohibited from covering anti-obesity medications. Most commercial plans cover Ozempic for type 2 diabetes but require prior authorization and step therapy for Wegovy. Only a minority of employer-sponsored plans have added obesity pharmacotherapy coverage since the AHA/ACC obesity guidelines update.

Novo Nordisk offers a savings card for Wegovy that brings out-of-pocket costs to as low as $0 per month for eligible commercially insured patients, with a cap on the number of eligible fills. Patients should check eligibility at the manufacturer's website before assuming compounded semaglutide is the only affordable path.